USPTO serial 76298093
METRORING
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DEFORD, JEFFREY S
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with METRORING?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
COOLOCK, DUBLIN 17, IE
Other trademarks owned by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Rockaway, NJ
Rockaway, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James M. Gibson
FRANCINE MILLER DONOVAN & YEE LLP110 GREENE ST STE 700NEW YORK, NY 10012UNITED STATESGoods and services
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
- Other trademarks owned by Warner Chilcott, Inc.
- Other trademarks owned by Warner Chilcott, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named METRORING
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 19, 2020 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 21, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 22, 2004 | ABN4 | ABANDONMENT - AFTER INTER PARTES DECISION | — |
| Jul 8, 2004 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jul 8, 2004 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jul 8, 2004 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jun 23, 2004 | CFIT | CASE FILE IN TICRS | — |
| Apr 6, 2004 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 11, 2003 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Dec 11, 2003 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Dec 11, 2003 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jul 16, 2003 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jun 26, 2003 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 14, 2002 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Oct 23, 2002 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Aug 27, 2002 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jul 30, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 10, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 22, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 24, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 3, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2001 | DOCK | ASSIGNED TO EXAMINER | — |